|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 22, 2017 ) Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
For more information about this report: http://www.reportsweb.com/dermatology-therapeutics-drug-development-pipeline-review-2016 .
Scope
- Which companies are the most active within the pipeline for dermatology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00020801/sample .
Table of Contents
Publisher Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
Publisher Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34
Acne Vulgaris 34
Psoriasis 35
Atopic Dermatitis 36
Pipeline Products Glance 37
Inquire before Buying at http://www.reportsweb.com/inquiry&RW00020801/buying .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
